Frontiers | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Durvalumab (Imfinzi) Drug Information
Diagnostics | Free Full-Text | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy - ScienceDirect
Did You Know – IMFINZI® (durvalumab) for unresectable Stage 3 NSCLC
The ocular side effects of emerging oncology meds
Long-Term Side Effects of Immune Checkpoint Inhibitors - NCI
Durvalumab Side Effects: Common, Severe, Long Term
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer | Future Oncology
Reimagining Treatment for Unresectable Stage III Non-Small Cell Lung Cancer - Cancer Therapy Advisor
Management of Long-Term Immune-Related Toxicities Needed in NSCLC - ILCN.org (ILCN/WCLC)
Biomedicines | Free Full-Text | Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis
Immunotherapy: Pushing the Frontier of Cancer Medicine | AACR Cancer Progress Report
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin | Nature Communications
Tremelimumab/Durvalumab Plus Chemo Improves Survival in Metastatic NSCLC
GeparNUEVO: durvalumab plus neoadjuvant chemotherapy in TNBC demonstrates long-term clinical benefit - Onco Americas
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial ...
Education & Resources for Oncology Nurses – IMFINZI® (durvalumab)
Durvalumab Side Effects: Common, Severe, Long Term
Durvalumab (Imfinzi) Drug Information
Long-Term Side Effects of Immune Checkpoint Inhibitors - NCI
Durvalumab - Wikipedia
Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management | Cleveland Clinic Journal of Medicine
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence
